產(chǎn)品名稱 | 先天性脂肪代謝障礙蛋白2抗體(常染色體顯性遺傳痙攣性截癱17) |
英文名稱 | Anti-BSCL2/SPG17 |
規(guī)格 | 0.2ml/200μg |
濃度 | 1mg/1ml |
價(jià)格 | 來電可享受優(yōu)惠 |
英文名稱 Anti-BSCL2/SPG17
中文名稱 先天性脂肪代謝障礙蛋白2抗體(常染色體顯性遺傳痙攣性截癱17)
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Dog, Cow, Horse, Rabbit
產(chǎn)品類型 一抗
研究領(lǐng)域 心血管 細(xì)胞生物 免疫學(xué) 神經(jīng)生物學(xué) 細(xì)胞類型標(biāo)志物
蛋白分子量 predicted molecular weight: 44kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from humanBSCL2/SPG17
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 Preservative: 15mM Sodium Azide, Constituents: 1%BSA, 0.01M PBS, pH 7.4
產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
(石蠟切片需做抗原修復(fù))
not yet tested in other applications.
optimal dilutions/concentrations should be determined by theend user.
保存條件 Store at -229 °C for oneyear.
別 名 Bernardinelli Seip congenital lipodystrophy 2;Bernardinelli Seip congenital lipodystrophy type 2 protein; Bernardinelli-Seipcongenital lipodystrophy type 2 protein; BSCL 2; BSCL2; BSCL2_HUMAN; GNG3LG;HMN 5; HMN5; MGC4694; Seipin; Spastic paraplegia 17 (autosomal dominant);Spastic paraplegia 17 (Silver syndrome); Spastic paraplegia 17; Spasticparaplegia with amyotrophy of hands and feet (Silver syndrome); Spasticparaplegia with amyotrophy of hands and feet; SPG 17; SPG17.